Data from: iTRAQ-Based Quantitative Proteomic Analysis on S100 Calcium Binding Protein A2 in Metastasis of Laryngeal Cancer

Laryngeal cancer is the most frequent neoplasm in the head and neck region, with the vast majority of tumors originating from squamous cells. The survival rate of patients with laryngeal cancer has not improved substantially over the past 25 years. To acquire further knowledge regarding the molecules responsible for laryngeal cancer oncogenesis and, in turn, to improve target therapy?iTRAQ and mass spectrometry analysis were utilized to detect differences in protein expression from 15 paired laryngeal cancer and adjacent non-cancerous tissue samples. Using mass spectrometry analysis, the expression levels of 100 proteins in laryngeal cancer samples were distinct from the non-tumor, non-cancerous samples. Further validation of the differentially expressed proteins S100A2, KRT16, FGB and HSPB1 were carried out using quantitative real-time RT-PCR, immunoblot and immunohistochemistry. Functional analysis of one of the highly expressed proteins, S100 calcium binding protein A2 (S100A2), was performed using RNA interference. As a consequence, attenuated S100A2 expression enhanced the ability of HEp-2 cell lines to migrate and invade <i>in vitro</i>. Our investigation complements the current understanding of laryngeal cancer progression. Furthermore, this study supports the concept that enhanced expression of S100A2 may be a promising strategy in developing novel cancer therapeutic drugs.喉癌是头颈部最常见的恶性肿瘤，绝大多数肿瘤起源于鳞状细胞。过去25年间，喉癌患者的生存率未得到显著改善。为深入阐明喉癌发生的分子机制，进而优化靶向治疗策略，本研究采用同位素相对和绝对定量标记（iTRAQ）联合质谱分析（mass spectrometry）技术，对15对配对的喉癌组织及癌旁正常组织的蛋白表达差异进行检测。经质谱分析发现，喉癌样本中有100种蛋白的表达水平与非肿瘤性正常组织存在显著差异。随后，研究者通过实时定量逆转录聚合酶链反应（quantitative real-time RT-PCR）、免疫印迹（immunoblot）及免疫组织化学（immunohistochemistry）对S100A2、KRT16、FGB及HSPB1这四种差异表达蛋白进行了验证。针对高表达蛋白S100钙结合蛋白A2（S100A2），本研究利用RNA干扰（RNA interference）技术开展功能学分析。结果显示，下调S100A2的表达可增强HEp-2细胞系的体外（in vitro）迁移与侵袭能力。本研究补充了当前对喉癌进展的认知，同时证实S100A2的高表达有望成为开发新型抗癌治疗药物的潜在靶点。